| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1111/J.1399-0012.2006.00570.X |
| P698 | PubMed publication ID | 17100731 |
| P50 | author | Jordi Ochando | Q48546528 |
| P2093 | author name string | Jonathan S Bromberg | |
| Adam C Yopp | |||
| Levi G Ledgerwood | |||
| P2860 | cites work | Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement | Q24671831 |
| Cell type-specific localization of human cardiac S1P receptors | Q28215436 | ||
| Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists | Q29618071 | ||
| Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 | Q29619644 | ||
| Sphingosine 1-phosphate analogs as receptor antagonists | Q30435361 | ||
| Regulatory T cells: key controllers of immunologic self-tolerance | Q33941140 | ||
| Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors | Q34126142 | ||
| Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. | Q34227743 | ||
| Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases | Q34234281 | ||
| The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2 | Q34274256 | ||
| A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists | Q34379081 | ||
| Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720. | Q34756546 | ||
| Leukotrienes, sphingolipids, and leukocyte trafficking | Q35158397 | ||
| FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. | Q35804361 | ||
| Update on liver transplantation using cyclosporine | Q35994591 | ||
| Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network | Q36184401 | ||
| Molecular mechanisms of lymphocyte homing to peripheral lymph nodes | Q36400133 | ||
| FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes | Q39741057 | ||
| The immune modulator FTY720 targets sphingosine 1-phosphate receptors | Q40736684 | ||
| FTY 720 prevents ischemic reperfusion damage in rat kidneys | Q43552719 | ||
| Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses | Q43746398 | ||
| Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. | Q44002416 | ||
| Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells | Q44368643 | ||
| Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment | Q44370378 | ||
| Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. | Q44482860 | ||
| Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. | Q44493644 | ||
| Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study | Q44616726 | ||
| The natural history of chronic allograft nephropathy | Q44688416 | ||
| Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate | Q44734550 | ||
| The effect of immunomodulators on prevention of autoimmune diabetes is stage dependent: FTY720 prevents diabetes at three different stages in the diabetes-resistant biobreeding rat. | Q44813941 | ||
| Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720. | Q44900766 | ||
| FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation | Q44956732 | ||
| FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. | Q45214556 | ||
| The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. | Q45262225 | ||
| The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity | Q46249644 | ||
| A novel immunomodulator, FTY720, prevents development of experimental autoimmune myasthenia gravis in C57BL/6 mice. | Q46415076 | ||
| Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. | Q46499903 | ||
| Cardiovascular risk estimates and risk factors in renal transplant recipients | Q46512845 | ||
| Sphingosine 1-phosphate receptors regulate chemokine-driven transendothelial migration of lymph node but not splenic T cells. | Q46664082 | ||
| Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes | Q46815005 | ||
| P433 | issue | 6 | |
| P921 | main subject | immunosuppression | Q1455316 |
| P304 | page(s) | 788-795 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Clinical Transplantation | Q15754920 |
| P1476 | title | Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants | |
| P478 | volume | 20 |
| Q46366717 | A ceramide-1-phosphate analogue, PCERA-1, simultaneously suppresses tumour necrosis factor-alpha and induces interleukin-10 production in activated macrophages |
| Q36875875 | Adhesion molecules in cutaneous immunity |
| Q36499684 | Airway CD8(+) T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity |
| Q34974825 | Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner |
| Q34792987 | Diminished Memory T-Cell Expansion Due to Delayed Kinetics of Antigen Expression by Lentivectors |
| Q46914095 | Early attenuation of lesional interleukin-16 up-regulation by dexamethasone and FTY720 in experimental traumatic brain injury. |
| Q36462344 | FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection on its withdrawal |
| Q43262877 | FTY720, a sphingosine 1-phosphate receptor modulator, inhibits CD1d-restricted NKT cells by suppressing cytokine production but not migration |
| Q24648847 | Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro |
| Q36384836 | Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). |
| Q37496801 | Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection |
| Q26785848 | Lymphatic disorders after renal transplantation: new insights for an old complication |
| Q35214194 | Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursors |
| Q46434977 | Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival |
| Q33651898 | Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations. |
| Q36473213 | The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment |
| Q44581309 | The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients? |
| Q84744062 | The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane glomerulonephritis |
| Q36955927 | Update on immunosuppressive drugs used in solid-organ transplantation and their nutrition implications |
Search more.